Thus, modification of antigen-encoding peptides with C16:0 provides a multi-pronged improvement of antigen-specific CTL responses, CD4+ T cell activity, and recognition of tumor cells, affecting both the induction and effector phase of anti-cancer immunity. Here, CD4 is linked to cancer.